2 terminated, 1 recruiting, 1 unknown. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Terminated 2, Recruiting 1, Unknown 1 |
| Phase 2 | 2 | Recruiting 1, Unknown 1 |
Follow Lung Neoplasm Malignant: new trials by email Literature Review of Lung Neoplasm Malignant trials Research Report on Lung Neoplasm Malignant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) MK-1084, Patritumab deruxtecan, Sacituzumab tirumotecan - Lung Neoplasm Malignant | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 140 | 2026-04-30 | 2026-10-01 |
| (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations BLU-451, Carboplatin, Pemetrexed - Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 103 | 2022-03-04 | 2025-02-10 |
| Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors SAR443216 IV, SAR443216 SC - Neoplasm Malignant, Breast Cancer | Phase 1 | Terminated | Sanofi | 44 | 2021-08-16 | 2025-09-15 |
| Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC CAR-T Cells, CAR-T combining PD-1 Knockout, PD-1 knockout - Lung Neoplasm Malignant, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | The First Affiliated Hospital of Guangdong Pharmaceutical University | 60 | 2018-02-01 | 2018-05-16 |
Lung Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (2) · Neoplasms (2) · Adenocarcinoma (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Lung Diseases (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Stomach Neoplasms (1)
Lung Diseases (3) · Neoplasms by Site (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3) · Neoplasms (2) · Brain Diseases (1) · Breast Diseases (1) · Bronchial Diseases (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1)
Carboplatin (1) · Cetuximab (1) · Immunotherapy, Adoptive (1) · Pemetrexed (1) · patritumab deruxtecan (1) · pembrolizumab (1)
Blueprint Medicines Corporation (1) · Merck Sharp & Dohme LLC (1) · Sanofi (1) · The First Affiliated Hospital of Guangdong Pharmaceutical University (1)
South Korea (3) · United States (3) · China (2) · Spain (2) · Taiwan (2) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · France (1) · Germany (1) · Greece (1) · Hong Kong (1) · Israel (1) · Italy (1)
2023 (1)